Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

2024

Survival Outcomes with Regorafenib and Trifluridine/Tipiracil in Metastatic Colorectal Cancer

Sample size: 1156 publication 10 minutes Evidence: moderate

Author Information

Author(s): Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, Alessandro Passardi, Giovanni Luca Frassineti, Alessandro Bittoni, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo, Cristina Morelli, Emanuela Dell’Aquila, Adele Artemi, Donatello Gemma, Domenico Cristiano Corsi, Alessandra Emiliani, Marta Ribelli, Federica Mazzuca, Giulia Arrivi, Federica Zoratto, Mario Giovanni Chilelli, Marta Schirripa, Maria Grazia Morandi, Fiorenza Santamaria, Manuela Dettori, Antonella Cosimati, Rosa Saltarelli, Alessandro Minelli, Emanuela Lucci-Cordisco, Michele Basso

Hypothesis

Does rechallenge therapy improve survival outcomes in metastatic colorectal cancer patients treated with regorafenib and trifluridine/tipiracil?

Conclusion

Rechallenge therapy may improve survival rates in the third-line treatment of metastatic colorectal cancer, especially when administered before sequential regorafenib and trifluridine/tipiracil treatment.

Supporting Evidence

981 patients underwent T and/or R therapy, while 175 patients had therapy rechallenge before T and/or R.
The median overall survival for patients treated with T/R and R/T sequences in the rechallenge therapy cohort was 14.5 months and 17.6 months, respectively.
A statistically significant survival benefit was observed in patients who received monotherapy with R compared to the T group.
In the no-rechallenge cohort, the mOS was statistically longer in the R/T sequence than in the T/R sequence.
The study suggests that rechallenge therapy may improve survival rates in the third-line treatment of mCRC.

Takeaway

This study looked at how well certain cancer treatments work for patients whose previous treatments didn't work. It found that giving some treatments again can help patients live longer.

Methodology

The study analyzed medical records of 1156 patients with refractory metastatic colorectal cancer from 17 Italian centers between 2012 and 2023, comparing survival outcomes based on treatment sequences.